Ipertrofia prostatica benigna e Mepartricina

Translated title of the contribution: Benign prostate hypertrophy and Mepartricin

A. F. De Rose, G. Carmignani

Research output: Contribution to journalArticle

Abstract

Estrogens can lead to benign prostatic hypertrophy (BPH) through two different ways: a) acting directly on stroma by specific receptors; b) increasing DHT prostatic receptors. Mepartricin performs an anti-estrogenic action at intestinal level only, increasing fecal excretion and reducing their serum and prostatic level. A European study evaluated 178 patients, 88 treated with Mepartricin and 98 with placebo. The group treated with Mepartricin showed from the first month a better urinary flow and a significant decrease of IPSS score.

Translated title of the contributionBenign prostate hypertrophy and Mepartricin
Original languageItalian
Pages (from-to)51-53
Number of pages3
JournalRivista Italiana di Biologia e Medicina
Volume17
Issue number3-4
Publication statusPublished - 1997

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Benign prostate hypertrophy and Mepartricin'. Together they form a unique fingerprint.

  • Cite this

    De Rose, A. F., & Carmignani, G. (1997). Ipertrofia prostatica benigna e Mepartricina. Rivista Italiana di Biologia e Medicina, 17(3-4), 51-53.